The MS Academy draws on a team of expert professionals with a rich blend of skills in treating and managing patients with MS.
Many of our speakers have a background in both clinical and research work, and so bring to bear both their practical experience as well as their knowledge about the evidence base for managing MS.
With speakers from a wide range of areas, the MasterClasses provide broad training for any professional with an interest in honing their MS knowledge and skills.
Sessions are delivered in groups of between 20 and 30, with a relaxed atmosphere and plenty of opportunity for questions and discussion. Speakers make particular use of video and case histories to enable delegates to explore advanced questions about MS care.
Click on the videos below to discover some of the subject areas that the Academy offers.
Giles Elrington presents of diagnosing and undiagnosing MS. This includes knowing when to consider a diagnosis of MS, an approach to aid diagnosis of MS, identifying management pathways, understanding the principles of the ‘giving’ of the diagnosis to patients and carers, and an approach to undiagnosing the disease too.
“Giles is always entertaining and engaging, he has a unique perspective on things which is refreshing. A very helpful session.”
MS treatment guidelines & the role of DMTs
Dr David Rog gives a review of the current treatment guidelines for disease-modifying treatments. He explores how the current Blueteq reimbursement criteria for DMTs have arisen, and how you can document your assessments of relapses to survive an external
audit, in particular if funding arrangements change for DMTs.
“Really useful to be aware of the revolution and progression of legislation, recommendation and documentation.”
Neuroimaging in MS
Dr David Paling MRI for diagnosis, earlier, specific about diagnosis, identify the right patients for treatment, and monitoring to ensure the right treatment decision and to ensure patients are safe.
“Very useful overview and update. Helpful tips for improving how to monitor patients with imagining and how to better prognosticate.”
Pharmacovigilance in MS treatment
Sarah White, clinical MS nurse specialist, explains why pharmacovigilance is important, what pharmacovigilance means in practice, as illustrated through case studies, and the implications this has for service delivery, plus considering practical ways in which to set up a safe and effective monitoring service.
“Very much a relevance to my work and a reflection of my own challenges.”
A comprehensive MS service
Dr Waqar Rashid’s session is about developing a comprehensive MS service, providing a framework with which to structure an MS service to meet the needs of patients and an outline of the contents of a toolbox that can be used to support development of services.
“Useful session, highlights the challenges of the MS service.”
“Very good in highlighting and helping us in organisation and service development at our trust “
Managing MS relapses
Dr Ben Turner discusses how to manage MS relapses, looking at facts and figures of relapses, evidence of intervention and options of best management for MS relapses.
“A well delivered session with helpful advice for running MS-relapse services.”
“I found the course very useful. the need to document what is classified as a relapse in order to justify escalation of therapies was something I probably did not do sufficiently before.”
The patient perspective
Dr David Paling speaks to patients about their perspective on MS and the useful takeaway points for clinicians in the practice, including:
- How people with MS feel prior to and at the time of diagnosis.
- How people with MS understand and weigh up information about treatment.
- How interactions with health care practitioners can both improve and worsen people with MS’s experience of their disease.
“The patient showed great courage in attending the session and sharing experiences. Raised interesting dilemma as to the balance between patient’s choice and choice of treatment.”
MS epidemiology & health economics
Professor Neil Robertson highlights the increased incidence of MS and the effect of population growth and increased longevity, reviews the economic cost of the disease including both direct and indirect costs, and explores how changing epidemiology will impact services and staff needs.
“Clear and incisive discussion.”
MS case histories
Professor Gavin Giovannoni, MS Academy academic director, outlines case studies for diagnosis, MDT management, symptom management and late stage MS. He considers the range of drugs used in the management of MS and practical solutions for the problems patients with MS experience.
“Gosh! I certainly learnt a lot more about MS that I never thought possible. Fascinating presentation, I certainly need to read up a lot more.”
“Thought provoking and a very useful insight into the dilemmas of the MS specialist.”